The Off-Patent Drugs Bill has been guillotined in its second reading in the House of Commons after it did not have Government support. Introduced by an MP as a Private Members Bill, it would have sought to enable pharma to obtain a new licence for medicines that were no longer on patent where there was evidence of effectiveness in new indications. According to Jonathan Evans MP, who brought the Bill to Parliament, this could have revolutionised access to treatments where there was little incentive for pharma to get new licences for old drugs that were no longer patent protected. The hope was that this could have been to help in the fight against other diseases where patients only receive access from off-label prescriptions. Supporters of the Bill claim it could enable new approaches for treating various diseases while saving millions of pounds for the NHS. It remains to be seen whether it will get anywhere, as Private Members Bills often do not get much traction.